Novel options for the pharmacological treatment of chronic anal fissure - Role of botulin toxin

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 47-52

  Madalinski, Mariusz ^a   Kalinowski, Leszek ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Anal fissure; Botulinum toxin; Nitric oxide; Pharmacological sphincterectomy; Rho kinase

Indexed keywords

ADENINE; ALDEHYDE DEHYDROGENASE; BETHANECHOL; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXOENZYME C3; GLYCERYL TRINITRATE; INDORAMIN; ISOSORBIDE DINITRATE; MINOXIDIL; NIFEDIPINE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SILDENAFIL; TREQUINSIN; VINPOCETINE; ZAPRINAST; NITRIC OXIDE DONOR; VASODILATOR AGENT;

ANORECTAL PRESSURE; ANUS FISSURE; ANUS SPHINCTER; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; FLUSHING; HUMAN; HYPOXIA; MICROCIRCULATION; NERVE ENDING; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; SPHINCTEROTOMY; CHRONIC DISEASE; DRUG EFFECT; TOPICAL DRUG ADMINISTRATION; WOUND HEALING;

ADMINISTRATION, TOPICAL; BOTULINUM TOXINS; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; FISSURE IN ANO; HUMANS; NITRIC OXIDE DONORS; VASODILATOR AGENTS; WOUND HEALING;

EID: 65549148096     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236083     Document Type: Review

References (76)

1. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 2004; 19(Suppl 8): S2-6.
2. Jost WH, Schimrigk K. Use of botulinum toxin in anal fissure. Dis Colon Rectum 1993; 36: 974.
3. Madalinski M. Nonsurgical treatment modalities for chronic anal fissure using botulinum toxin. Gastroenterology 1999; 117: 516-7.
4. Brisinda G, Cadeddu F, Brandara F, Brisinda D, Maria G. Treating chronic anal fissure with botulinum neurotoxin. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 82-9.
5. Dziki A, Trzcinski R, Langner E, Wronski W. New approaches to the treatment of anal fissure. Acta Chir Iugosl 2002; 49: 73-5.
6. Lund JN, Scholefield JH. Internal sphincter spasm in anal fissure. Br J Surg 1997; 84: 1723-4.
7. Jost WH, Schimrigk K. Therapy of anal fissure using botulin toxin. Dis Colon Rectum 1994; 37: 1321-4.
8. Klosterhalfen B, Vogel P, Rixen H, Mittermayer C. Topography of the inferior rectal artery: a possible cause of chronic, primary anal fissure. Dis Colon Rectum 1989; 32: 43-52.
9. Schouten WR, Briel JW, Auwerda JJA, DeGraaf EJR. Ischaemic nature of anal fissure. Br J Surg 1996; 83: 63-5.
10. Hill KK, Smith TJ, Helma CH, et al. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol 2007; 189: 818-32.
11. Singh BR. Molecular basis of the unique endopeptidase activity of botulinum neurotoxin. In: Brin MF, Hallett M, Jankovic J. eds. Scientific and therapeutic aspects of botulinum toxin. 1st ed. Philadelphia: Lippincott Williams & Wilkins, 2002; 75-88.
12. Munchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ 2000; 320: 161-5.
13. Dressler D, Saberi AF. Botulinum toxin: mechanisms of action. Eur Neurol 2005; 53: 3-9.
14. Madaliński MH. Botulinum toxin for the treatment of upper gastrointestinal diseases: the future or already the past? Endoscopy 2003; 35: 366-7.
15. Popoff MR, Hauser D, Boquet P, Eklund MW, Gill DM. Characterization of the C3 gene of Clostridium botulinum types C and D and its expression in Escherichia coli. Infect Immun 1991; 59: 3673-9.
16. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208.
17. Patel CA, Rattan S. Cellular regulation of basal tone in internal anal sphincter smooth muscle by RhoA/ROCK. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1747-56.
18. Torfgård KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1994; 8: 701-17.
19. Lund JN, Armitage NC, Scholefield JH. Use of glyceryl trinitrate ointment in the treatment of anal issure. Br J Surg 1996; 83: 776-7.
20. Gorfine SR. Treatment of benign anal disease with topical nitroglycerin. Dis Colon Rectum 1995; 38: 453-6; discussion 456-7.
21. Gorfine SR. Topical nitroglycerin therapy for anal fissures and ulcers. N Engl J Med 1995; 333: 1156-7.
22. Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. Lancet 1997; 349: 11-4.
23. Lysy J, Israelit-Yatzkan Y, Sestiery-Ittah M, Weksler-Zangen S, Keret D, Goldin E. Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure. Gut 2001; 48: 221-4.
24. Lysy J, Israelit-Yatzkan Y, Sestiere-Ittah M, Keret D, Goldin E. Treatment of chronic anal fissure with isosorbide dinitrate: long-term results and dose determination. Dis Colon Rectum 1998; 41: 1406-10.
25. Songun I, Boutkan H, Delemarre JBVM, Breslau PJ. Effect of isosorbide dinitrate ointment on anal fissure. Dig Surg 2003; 20: 122-6.
26. Parellada C. Randomized, prospective trial comparing 0.2 percent isosorbide dinitrate ointment with sphincterotomy in treatment of chronic anal fissure: a two-year follow-up. Dis Colon Rectum 2004; 47: 437-43.
27. Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure. Dis Colon Rectum 2003; 46: 805-8.
28. Bielecki K, Kolodziejczak M. A prospective randomized trial of diltiazem and glyceryltrinitrate ointment in the treatment of chronic anal fissure. Colorectal Dis 2003; 5: 256-7.
29. Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med 1999; 341: 65-9.
30. O'Kelly T, Brading A, Mortensen N. Nerve mediated relaxation of the human internal anal sphincter: the role of nitric oxide. Gut 1993; 34: 689-93.
31. Gosselink MP, Darby M, Zimmerman DD, Gruss HJ, Schouten WR. Treatment of chronic anal fissure by application of L-arginine gel: a phase II study in 15 patients. Dis Colon Rectum 2005; 48: 832-7.
32. Madaliński M, Sławek J, Adrich Z, Kryszewski A. Why can topical Glyceryl Trinitrate and Botulinum toxin be ineffective in treatment of chronic anal fissure. 7th United European Gastroenterology Week. Gut 1999: 45(Suppl V): A304.
33. Madaliński M, Sławek J, Zbytek B, et al. Topical nitrates and the higher doses of botulinum toxin for chronic anal fissure. Hepato-Gastroenterology 2001; 48: 977-9.
34. Brisinda G, Maria G, Sganga G, Bentivoglio AR, Albanese A, Castagneto M. Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery 2002; 131: 179-84.
35. Witte ME, Klaase JM. Botulinum toxin A injection in ISDN ointment-resistant chronic anal fissures. Dig Surg 2007; 24: 197-201.
36. Carapeti EA, Kamm MA, Phillips RK. Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects. Dis Colon Rectum 2000; 43: 1359-62.
37. Griffin N, Acheson AG, Jonas M, Scholefield JH. The role of topical diltiazem in the treatment of chronic anal fissures that have failed glyceryl trinitrate therapy. Colorectal Dis 2002; 4: 430-5.
38. Garry A, Fromy B, Blondeau N, et al. Altered acetylcholine, bradykinin and cutaneous pressure-induced vasodilation in mice lacking the TREK1 potassium channel: the endothelial link. EMBO Rep 2007; 8: 354-9.
39. Muthukumarassamy R, Robinson SS, Sarath SC, Raveendran R. Treatment of anal fissures using a combination of minoxidil and lignocaine: a randomized, double-blind trial. Indian J Gastroenterol 2005; 24: 158-60.
40. Khaikin M, Yebara S, Bashankaev B, et al. Topical Captopril Cream: A New Treatment for Anal Fissure? The First Human Study. Dis Colon Rectum 2007; 50: 747.
41. Jones OM, Brading AF, McC Mortensen NJ. Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro. Dis Colon Rectum 2002; 45: 530-6.
42. Takimoto E, Belardi D, Tocchetti CG, et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007; 115: 2159-67.
43. Torrabadella L, Salgado G, Burns RW, Berman IR. Manometric study of topical sildenafil (Viagra) in patients with chronic anal fissure: sildenafil reduces anal resting tone. Dis Colon Rectum 2004; 47: 733-8.
44. Pitt J, Craggs MM, Henry MM, Boulos PB. Alpha1-adrenoceptor blockade: potential new treatment for anal fissures. Dis Colon Rectum 2000; 43: 800-3.
45. Pitt J, Dawson PM, Hallan RI, Boulos PB. A doubleblind randomized placebo-controlled trial of oral indoramin to treat chronic anal fissure. Colorectal Dis 2001; 3: 165-8.
46. Rob HP, Hilgers RHP, Webb RC. Molecular Aspects of Arterial Smooth Muscle Contraction: Focus on Rho. Exp Biol Med (Maywood) 2005; 230: 829-35.
47. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001; 281: H2124-32.
48. Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, Albanese A. Botulinum toxin for chronic anal fissure. Lancet 1994; 344: 1127-8.
49. Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. Botulinum toxin injections in the internal anal sphincter for the treatment of chronic anal fissure: long-term results after two different dosage regimens. Ann Surg 1998; 228: 664-9.
50. Jost WH, Schimrigk K: Botulinum toxin in therapy of anal fissure. Lancet 1995; 345: 188-9.
51. Schäfer A, Enck P, Fürst G, Kahn T, Frieling T, Lübke HJ. Anatomy of the anal sphincters. Comparison of anal endosonography to magnetic resonance imaging. Dis Colon Rectum 1994; 37: 777-81.
52. Fletcher JG, Busse RF, Riederer SJ, et al. Magnetic resonance imaging of anatomic and dynamic defects of the pelvic floor in defecatory disorders. Am J Gastroenterol 2003; 98: 399-411.
53. Jost WH: Influence of botulinum toxin injections on the sphincteric compound muscle action potential of the external anal sphincter. Dis Colon Rectum 1997; 40: 995-6.
54. Shaari ChM, Sanders I. Assessment of the biological activity of botulinum toxin. In: Jankovic J, Hallet M Eds. Therapy with botulinum toxin. New York: Dekker 1994; 159-70.
55. Ho KS, Ho YH. Randomized clinical trial comparing oral nifedipine with lateral anal sphincterotomy and tailored sphincterotomy in the treatment of chronic anal fissure. Br J Surg 2005; 92: 403-8.
56. Pascual M, Pera M, Courtier R, et al. Endosonographic and manometric evaluation of internal anal sphincter in patients with chronic anal fissure and its correlation with clinical outcome after topical glyceryl trinitrate therapy. Int J Colorectal Dis 2007; 22: 963-7.
57. Thornton J, Kennedy ML, King DW. Prospective manometric assessment of botulinum toxin and its correlation with healing of chronic anal fissure. Dis Colon Rectum 2005; 48: 1207-12.
58. Madalinski M, Chodorowski Z. Relation between botulinum toxin and nitric oxide donors in the treatment of the chronic anal fissure. Med Sci Monit 2005; 11: HY1-HY5.
59. Bassenge E: Endothelial function in different organs. Prog Cardiovasc Dis 1996; 39: 209-28
60. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19: 488-96.
61. Essler M, Linder S, Schell B, et al. Cytotoxic necrotizing factor 1 of Escherichia coli stimulates Rho/Rho-kinase-dependent myosin light-chain phosphorylation without inactivating myosin light-chain phosphatase in endothelial cells. Infect Immun 2003; 71: 5188-93.
62. Takemoto M, Sun, Hiroki J, Shimokawa H, Liao JK. Rho-Kinase Mediates Hypoxia-Induced Downregulation of Endothelial Nitric Oxide Synthase. Circulation 2002; 106: 57-62.
63. Lund JN, Scholefield JH. Aetiology and treatment of anal fissure. Br J Surg 1996; 83: 1335-44.
64. Yang TY, Jang TY. The value of local botulinum toxin A injection in the treatment of the pain of aphthous ulcer. Eur Arch Otorhinolaryngol 2008.
65. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64: 274-83.
66. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 1403-6.
67. Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol 2007; 85: 209-14.
68. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008; 101: 366-70.
69. Takemoto M, Sun Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62.
70. Strijdom H, Friedrich SO, Hattingh S, Chamane N, Lochner A. Hypoxia-induced regulation of nitric oxide synthase in cardiac endothelial cells and myocytes and the role of the PI3-K/PKB pathway. Mol Cell Biochem 2008; Sep 14.
71. Essler M, Amano M, Kruse HJ, Kaibuchi K, Weber PC, Aepfelbacher M. Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells. J Biol Chem 1998; 273: 21867-74.
72. Hains MD, Wing MR, Maddileti S, Siderovski DP, Harden TK. Galpha12/13- and rho-dependent activation of phospholipase C-epsilon by lysophosphatidic acid and thrombin receptors. Mol Pharmacol 2006; 69: 2068-75.
73. 2+ sensitization in rat ileal longitudinal smooth muscle. Am J Physiol Gastrointest Liver Physiol 2007; 293: G699-710.
74. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83: 1325-58.
75. Zhang J, Chen Z, Cobb FR, Stamler JS. Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. Circulation 2004; 110: 750-5.
76. Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA, Shellman YG. RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol 2006; 126: 862-8.